Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Q2 Revenues Grow 8 Percent

NEW YORK (GenomeWeb) – Interpace Diagnostics today reported an 8 percent year over year increase in revenues for the second quarter.

For the three months ended June 30, the molecular diagnostics and pathology services firm posted $3.9 million in revenues, up from $3.6 million in the year-ago period.

In a statement, Interpace President and CEO Jack Stover noted the firm raised an additional $13.7 million in capital during the quarter, "eliminating all long-term debt and related possible royalties and milestone obligations while continuing to make good commercial progress. … We are now well-positioned to leverage our commercial resources and further build out our platforms."

During the quarter, the firm secured payor coverage for its tests with UnitedHealthcare, Premera Blue Cross, and Aetna. In July, Interpace said that Cigna would cover its ThyGenX molecular thyroid test.

Interpace's R&D spending in Q2 2017 rose 16 percent year over year to $413,000 from $357,000, while its SG&A costs grew 30 percent to $4.3 million from $3.3 million.

Interpace posted a net loss of $6.3 million, or $.65 per share, for the recently completed quarter, compared to a net loss of $2.3 million, or $1.29 per share, in the year-ago period. The firm used nearly 9.7 million shares to calculate its loss per share for Q2 2017, compared to 1.8 million shares in Q2 2016.

As of June 30, Interpace had $14.3 million in cash and cash equivalents.

In late morning trading on the Nasdaq, shares of Interpace rose a fraction of 1 percent to $.88.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.